Neuraxis

Neuraxis Equity Ratio

The Equity Ratio of Neuraxis (NRXS) as of Nov 16, 2026 is 53.08 %. In the previous year, Equity Ratio was 43.46 % — a change of 22.13% (higher).

Equity Ratio

53.08 %

YoY

22.13%

Last updated:

Equity Ratio of Neuraxis is 2025 53.08 % . Equity Ratio of Neuraxis was 2024 43.46 % . It decreases by 22.13% higher compared to the previous year.

The Neuraxis Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2020
58.92 USD
Jan 1, 2021
-108.57 USD
Jan 1, 2022
-376.43 USD
Jan 1, 2023
-275.42 USD
Jan 1, 2024
43.46 USD
Jan 1, 2025
53.08 USD
The Neuraxis Equity Ratio history
YEAREquity RatioYoY
53.08 %+22.13%
43.46 %-115.78%
-275.42 %-26.83%
-376.43 %+246.72%
-108.57 %-284.25%
58.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Equity Ratio of Neuraxis is 53.08 % in 2025.

Equity Ratio of Neuraxis changed from 43.46 % to 53.08 %, representing a 22.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Neuraxis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neuraxis

All Key Metrics — Neuraxis